Understanding harmful cells in lung scarring
Cellular and molecular delineation of pathologic fibroblasts in pulmonary fibrosis
This study is looking at certain cells in the lungs that cause scarring in pulmonary fibrosis, and by using special techniques, researchers hope to learn more about these cells to find better ways to treat the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10885214 on NIH RePORTER |
What this research studies
This research investigates the role of specific fibroblast cells that contribute to lung scarring in pulmonary fibrosis, a serious lung disease. By using advanced techniques like single-cell RNA sequencing, the study aims to identify and characterize these pathologic fibroblasts, which are responsible for excessive collagen production. The researchers have developed a unique mouse model to manipulate these cells and better understand their behavior and impact on lung function. This knowledge could lead to new therapeutic strategies to target and treat pulmonary fibrosis more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis, particularly those experiencing significant lung function decline.
Not a fit: Patients with other forms of lung disease or those without a diagnosis of pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that specifically target harmful fibroblast cells, potentially improving outcomes for patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in targeting specific cell types in fibrotic diseases, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Tsukui, Tatsuya — University of California, San Francisco
- Study coordinator: Tsukui, Tatsuya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.